Opthea to Participate in Citi 2024 Global Healthcare Conference
Opthea (ASX/NASDAQ:OPT), a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases including wet age-related macular degeneration, has announced its participation in the Citi 2024 Global Healthcare Conference. CEO Fred Guerard will conduct one-on-one investor meetings and participate in a panel titled 'Eyes Wide Open on Ophthalmology' on December 5, 2024, at 1:45 PM ET in Miami, Florida. The presentation will be available for viewing on the company's website in the Events & Presentations section.
Opthea (ASX/NASDAQ:OPT), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di trattamenti per le malattie retiniche, tra cui la degenerazione maculare legata all'età umida, ha annunciato la sua partecipazione alla Citi 2024 Global Healthcare Conference. Il CEO Fred Guerard condurrà incontri individuali con gli investitori e parteciperà a un panel intitolato 'Eyes Wide Open on Ophthalmology' il 5 dicembre 2024, alle 13:45 ET a Miami, Florida. La presentazione sarà disponibile per la visione sul sito web dell'azienda nella sezione Eventi e Presentazioni.
Opthea (ASX/NASDAQ:OPT), una compañía biofarmacéutica en etapa clínica centrada en desarrollar tratamientos para enfermedades retinianas, incluyendo la degeneración macular relacionada con la edad húmeda, ha anunciado su participación en la Citi 2024 Global Healthcare Conference. El CEO Fred Guerard llevará a cabo reuniones individuales con inversores y participará en un panel titulado 'Eyes Wide Open on Ophthalmology' el 5 de diciembre de 2024, a la 1:45 PM ET en Miami, Florida. La presentación estará disponible para su visualización en el sitio web de la compañía en la sección de Eventos y Presentaciones.
Opthea (ASX/NASDAQ:OPT)는 습성 노인성 황반퇴행성 질환을 포함한 망막 질환 치료제를 개발하는 임상 단계의 생물 의약품 회사로, Citi 2024 Global Healthcare Conference에 참여한다고 발표했습니다. CEO인 Fred Guerard는 개인 투자자와의 미팅을 진행하고, 2024년 12월 5일 오후 1시 45분 ET에 마이애미, 플로리다에서 'Eyes Wide Open on Ophthalmology'라는 제목의 패널에 참여할 예정입니다. 발표 내용은 회사 웹사이트의 이벤트 및 발표 섹션에서 확인할 수 있습니다.
Opthea (ASX/NASDAQ:OPT), une entreprise biopharmaceutique en phase clinique axée sur le développement de traitements pour les maladies rétiniennes, y compris la dégénérescence maculaire liée à l'âge humide, a annoncé sa participation à la Citi 2024 Global Healthcare Conference. Le PDG Fred Guerard effectuera des réunions individuelles avec les investisseurs et participera à une table ronde intitulée 'Eyes Wide Open on Ophthalmology' le 5 décembre 2024 à 13h45 ET à Miami, en Floride. La présentation sera disponible pour visionnage sur le site web de l'entreprise dans la section Événements et Présentations.
Opthea (ASX/NASDAQ:OPT), ein Unternehmen für biopharmazeutische Produkte in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für Netzhauterkrankungen, einschließlich feuchter altersbedingter Makuladegeneration, konzentriert, hat seine Teilnahme an der Citi 2024 Global Healthcare Conference bekannt gegeben. CEO Fred Guerard wird Einzelgespräche mit Investoren führen und an einem Panel mit dem Titel 'Eyes Wide Open on Ophthalmology' am 5. Dezember 2024 um 13:45 Uhr ET in Miami, Florida, teilnehmen. Die Präsentation wird auf der Website des Unternehmens im Bereich Veranstaltungen und Präsentationen zur Verfügung stehen.
- None.
- None.
MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Global Healthcare Conference on December 5, 2024 in Miami, Florida.
Details are as follows:
| Panel: | Eyes Wide Open on Ophthalmology |
| Presenter: | Frederic Guerard, PharmD, CEO, Opthea |
| Date: | Thursday, December 5, 2024, 1:45 PM ET |
The webcast will be accessible on the “Events & Presentations” section of the Company’s website at http://ir.opthea.com/.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
When is Opthea (OPT) presenting at the Citi 2024 Global Healthcare Conference?
What panel is Opthea (OPT) participating in at the Citi Healthcare Conference 2024?
Where can investors watch Opthea's (OPT) presentation at the Citi Healthcare Conference?
What type of diseases does Opthea (OPT) focus on treating?
